Psyomics
PsyOmics develops proteomic diagnostics to improve early diagnosis and treatment outcomes for those with neuropsychiatric disorders.
Psyomics has raised €13M across 3 funding rounds from 4 investors, most recently a Seed round in Oct 2025. Based in Cambridge, UK; founded 2015; active in Healthtech. Data as of 28 Oct 2026.
Total raised
€13M
€13,054,955
Funding rounds
3
Investors
4
distinct backers
Active since
2020-10
latest 2025-10
Funding by year
EUR raised per yearPsyomics — funding by year — interactive chart.
Data table
| Psyomics — funding by year | |
|---|---|
| 2020 | €1.7M |
| 2022 | €2.8M |
| 2025 | €8.6M |
Signals
Medium confidenceRaise-next likelihood75
base rate 44% for Seed
- ▲ In typical raise window
- ▲ Up-round momentum
Exit likelihood9
base rate 11% (2+ rounds)
- ▲ 11y since founding (typical exit age)
- ▼ No recent equity round (debt-only or quiet)
Timing: in window vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
3 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2025-10-10 | Seed | €8.6M | — | View deal → |
| 2022-06-21 | Other | €2.8M | Meltwind,Newable Ventures,Parkwalk Advisors | View deal → |
| 2020-10-27 | Other | €1.7M | Parkwalk Advisors | View deal → |